Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with prostate cancer that has been confirmed by a tissue sample as a specific type called adenocarcinoma (not rare types like small cell, neuroendocrine, or others)
• Doctors expect you to live for at least 3 months or more
• You are generally able to carry out daily activities with little or no restriction (as measured by a standard health scoring system called ECOG, rated 0 or 1)
• Your cancer can be measured or tracked using standard imaging methods
• You have already been treated with at least one hormone-blocking drug for prostate cancer, such as enzalutamide, darolutamide, apalutamide, or abiraterone acetate
• You have one or more cancer deposits (metastases) in the body that cannot be surgically removed
• You have had your testicles surgically removed and/or are on ongoing hormone-suppressing therapy, and your testosterone level is very low (below a specific threshold)
• Your prostate cancer has continued to grow or spread despite your most recent treatment
• Your kidneys, liver, and blood counts are functioning well enough to safely participate
• If you are sexually active with a partner who could become pregnant, you must use a condom (plus spermicide if available), avoid fathering a child, and not freeze or donate sperm during the trial; your partner is also recommended to use an additional contraceptive method

Additional requirements if joining Sub-study 1:

• You have only received one hormone-blocking drug (ARPI) so far
• A special type of scan (PSMA PET/CT scan) shows your cancer responds to a specific marker, with no areas that do not show up on this scan
• You are able to swallow and take tablets or capsules by yourself

Who may not be able to join:

• Your prostate cancer is a rare type other than adenocarcinoma (such as small cell, spindle cell, signet cell, neuroendocrine, or sarcomatous)
• You have a known blockage in your urinary tract that has not been treated
• Your cancer has spread to the brain
• You have cancer pressing on or threatening your spinal cord
• Your cancer has spread to the lining around the brain and spinal cord
• You have had, or currently have, a completely separate type of cancer in a different part of your body
• You have serious ongoing medical conditions at the same time (confirm with trial site)
• You have a history of scarring or inflammation of the lungs (not caused by infection)
• You have a history of, or signs suggesting, certain blood or bone marrow disorders (confirm with trial site)
• You still have significant side effects from a previous cancer treatment that have not resolved
• You are unable to swallow tablets or capsules, or have a digestive condition that would stop medication being absorbed properly
• You have an active infection, including tuberculosis, hepatitis B, or hepatitis C
• You have a known allergy or sensitivity to the study drug or any of its ingredients

Additional reasons you may not be able to join Sub-study 1:

• You have a history of seizures that are not well controlled, or you need more than two epilepsy medications
• You have had a severe brain injury or stroke in the past
• A bone scan shows a very widespread pattern of bone spread (called a "superscan")
• You have previously been treated with the specific drug AZD9574, or you have received more than one course of a type of drug called a PARP inhibitor

Important: Always verify eligibility with the trial site directly before applying.